ThermoGenesis Holdings to Present at the H.C. Wainwright 25th Annual Global Investment Conference

RANCHO CORDOVA, Calif., September 6, 2023 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chris Xu, Ph.D., Chief Executive Officer, will present a company overview on Wednesday, September 13, at 4:30 pm ET, during the H.C. Wainwright 25th Annual Global Investment Conference, taking place September 11-13, 2023, in New York.

Dr. Xu will also host in-person and virtual one-on-one meetings during the event. Institutional investors who are registered for the conference can log into to request a meeting with the company. Those interested in meeting with Dr. Xu outside of the conference should contact Michael Miller at

About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit:

Contact Information 

Company Contact:
Wendy Samford

Investor Relations Contact:
Paula Schwartz, Rx Communications